- Home
- MVF vs CRVS Comparison
MVF vs CRVS Comparison
Compare MVF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVF
- CRVS
- Stock Information
- Founded
- MVF 1988
- CRVS 2014
- Country
- MVF United States
- CRVS United States
- Employees
- MVF N/A
- CRVS N/A
- Industry
- MVF Investment Bankers/Brokers/Service
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MVF Finance
- CRVS Health Care
- Exchange
- MVF Nasdaq
- CRVS Nasdaq
- Market Cap
- MVF 380.7M
- CRVS 305.4M
- IPO Year
- MVF N/A
- CRVS 2016
- Fundamental
- Price
- MVF $6.57
- CRVS $4.11
- Analyst Decision
- MVF
- CRVS Strong Buy
- Analyst Count
- MVF 0
- CRVS 4
- Target Price
- MVF N/A
- CRVS $15.00
- AVG Volume (30 Days)
- MVF 162.8K
- CRVS 1.1M
- Earning Date
- MVF 01-01-0001
- CRVS 08-05-2025
- Dividend Yield
- MVF 4.11%
- CRVS N/A
- EPS Growth
- MVF N/A
- CRVS N/A
- EPS
- MVF N/A
- CRVS N/A
- Revenue
- MVF N/A
- CRVS N/A
- Revenue This Year
- MVF N/A
- CRVS N/A
- Revenue Next Year
- MVF N/A
- CRVS N/A
- P/E Ratio
- MVF N/A
- CRVS N/A
- Revenue Growth
- MVF N/A
- CRVS N/A
- 52 Week Low
- MVF $5.85
- CRVS $1.92
- 52 Week High
- MVF $7.19
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- MVF 45.57
- CRVS 53.94
- Support Level
- MVF $6.52
- CRVS $3.79
- Resistance Level
- MVF $6.61
- CRVS $4.31
- Average True Range (ATR)
- MVF 0.05
- CRVS 0.29
- MACD
- MVF 0.01
- CRVS 0.00
- Stochastic Oscillator
- MVF 60.77
- CRVS 72.64
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).